Vilobelimab Medicine 05 December 2023 Extended indication COVID-19 pneumonia Therapeutic value No estimate possible yet Total cost Registration phase Registration application pending Product Active substance Vilobelimab Domain Infectious diseases Reason of inclusion Indication extension IND Main indication COVID-19 Extended indication COVID-19 pneumonia Current proprietary name Already available biosimilars / generics Proprietary name Gohibic Manufacturer Portfolio holder Inflarx Mechanism of action Complement inhibitor Route of administration Intravenous Therapeutical formulation Intravenous drip Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Unknown Particularity Unknown ATMP No Submission date August 2023 Expected Registration September 2024 Orphan drug Yes Registration phase Registration application pending Reimbursement Medicine sluice Additional remarks NCT04333420 Therapeutic value Current treatment options Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration 800mg References Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost References Drugs.com Additional remarks De prijs voor Vilobelimab intraveneuze oplossing (10mg/mL) is $6,350 voor 80 milliliters. De prijs in de Verenigde Staten is vaak hoger dan in Nederland. Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks